SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed12d 8h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor RASONQUE's revenue trajectory in Q4 2026 as early-launch dynamics (EAP transition, waiting patients) normalize. EU approval decision and subsequent country-level launches will be key catalysts. Also watch for RASolve 301 (NSCLC) initial readout in 2027.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

RVMD drug pipeline →

daraxonrasib

▲ Bullish Named in this press release
Impact
Phase
Phase 3 (completed with positive results) / pre-NDA
Time to market
NDA submission pending; potential approval in 2L PDAC possibly by Q3 2026 per Truist analyst projection, though no PDUFA date is confirmed
Next catalyst
None dated

What to watchDaraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$177.65
T+0 close · Nov 4, 2026 · via day close
Latest settled
−0.73%
T+5 · $176.35 · next T+20 in 17d
Vs SPY
−4.02%
α at T+5
Latest observation
−7.21%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $177.65entry
  2. T+1 · 11d ago +8.24%α +7.92% · $192.28
  3. T+5 · 5d ago −0.73%α −4.02% · $176.35
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines reported Q3 2026 results with RASONQUE net product revenue of $197.6M from its first five weeks of commercial availability following FDA approval in August 2026. Net loss widened to $407.5M from $305.2M a year ago, driven by higher R&D and SG&A costs. The company reiterated full-year 2026 GAAP operating expense guidance of $2.1B-$2.2B.

Key Financial Metrics

EPS
−$1.90
est −$2.38 · +20.2%
Revenue
$197.6M
est $27.3M · +623.7%
Rating
beat

Key Facts

  • RASONQUE net product revenue of $197.6M for Q3 2026, reflecting ~5 weeks of commercial availability
  • FDA approved RASONQUE on August 26, 2026 for metastatic pancreatic cancer
  • Positive CHMP opinion recommending EU approval received in October 2026
  • Net loss of $407.5M in Q3 2026 vs $305.2M in Q3 2025
  • Cash, cash equivalents and marketable securities of $3.7B as of September 30, 2026
  • Received $250M first mandatory debt tranche from Royalty Pharma in October 2026
  • Full-year 2026 GAAP operating expense guidance reiterated at $2.1B-$2.2B
  • More than 5,000 unique patients received commercial RASONQUE through September 30, 2026

Financial Impact

RASONQUE generated $197.6M in net product revenue in its first ~5 weeks; net loss was $407.5M; cash balance $3.7B plus $250M received post-quarter

revenuenet losscash positionoperating expenses

Risk Factors

  • Early launch revenue includes one-time EAP transition and initial stocking, not indicative of steady-state run rate
  • R&D and SG&A expenses are rising rapidly with commercialization build-out
  • Net loss continues to widen; reliance on capital markets or milestone-based funding
  • Regulatory and reimbursement timelines in EU and Japan uncertain

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (31 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395785

Track record

44 reports on RVMD

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 17 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
  4. Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
  5. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
  6. Nov 4, 202612d ago 8-K Bullish 7/10 No price data
  7. Nov 4, 202612d ago Press Release Neutral 5/10 Viewing Entry $177.65 Now $166.87 −6.07% settles Feb 3
  8. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
  9. Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
  10. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
Showing 10 of 44

US Market Status

Market Closed · Opens in 8h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026